Cerviray AI, the AI-based cervical cancer screening system from AIDOT, a medical ICT company specializing in artificial intelligence, is launching full-scale field validation in Mongolia and expansion into global markets.

The validation is being carried out under the "2026 Gangwon AI Healthcare Global Innovation Special Zone Company Development Support Program." Its goal is to test the "On-Device AI" system on site and strengthen its technical robustness so that high-performance AI diagnostic services can be delivered reliably even in medically underserved areas.

Through the program, AIDOT plans to partner with five or more major public and private hospitals in Mongolia. Within a short period, it aims to build more than 50,000 cases of high-quality real-world data (RWD) that reflect extreme diagnostic conditions, such as variable lighting and unstable power supply.

Behind the project is Dr. Bayar (Dr. Bayarsaikhan, formerly of the National Cancer Center), Mongolia's leading authority in the field, who has devoted herself to eliminating cervical cancer in the country. The project also reflects the deep medical tradition of her family.

Many key local medical professionals and institutions have joined the collaboration. These include Ch. Munkhbayar, Director of Allergy-Med Hospital. He is a disciple of Dr. Luvsandorj, Dr. Bayar's father and an elder of the Mongolian medical community, and was awarded the title of "Honorary Doctor" by the Mongolian government for saving 301 high-risk mothers. ACH International Hospital, affiliated with the Mongolian National University of Medical Sciences, has also joined.

Unlike conventional cloud- or server-based systems, the on-device version of Cerviray AI runs entirely on the device itself, such as a tablet or a mid-range CPU. This means it works even in remote areas with poor internet connectivity, including grasslands, deserts, and mountainous regions.

The project will also validate a self-supervised learning approach. Original medical image data is never transferred abroad. Instead, it is processed and de-identified on local devices, and only the updated model weights are exchanged.

Through this approach, the company plans to propose an innovative, regulation-compliant model that flexibly addresses increasingly strict data sovereignty regulations in each country, such as the GDPR and Korea's Personal Information Protection Act.

"This Gangwon AI Healthcare Global Innovation Special Zone project will be an opportunity to create an unprecedented success model," said Jaehoon Jung, CEO of AIDOT. "It combines the noble dedication of Dr. Bayar's family, the expertise of Mongolia's top scholars, and AIDOT's on-device AI technology."

Korea Economic TV / September 15, 2026 / Jaejun Yang, Senior Reporter